Biotechnology News and Research

RSS

SynthRx to become wholly-owned subsidiary of ADVENTRX

ADVENTRX Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to acquire SynthRx, Inc., a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188.

14 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

Spinal cord sugar residues regulate growth and survival of nerve cells: Study

Researchers in Bochum have found out that certain sugar residues in the spinal cord regulate the growth and survival of nerve cells which control the movement of muscles. "We hope that our findings can improve regenerative treatment of nerve injuries", explains Prof. Dr. Stefan Wiese from the Molecular Cell Biology study group.

14 Feb 2011

Positive data from second study of predictive preterm birth biomarkers presented at SMFM meeting

Sera Prognostics, a women's health company developing diagnostic tests for early prediction of preterm birth and other pregnancy complications, today announced that preliminary analyses of data from a second study of predictive preterm birth biomarkers generally confirmed researchers' earlier results and were able to identify up to 92 percent of pregnant women who went on to have a preterm birth.

14 Feb 2011

Dyadic issued seventh U.S. patent

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").

11 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

11 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2010.

10 Feb 2011

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2010.

10 Feb 2011

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

10 Feb 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

10 Feb 2011

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.

10 Feb 2011

CHI commends FDA's recognition of more efficient regulatory pathway for innovative medical devices

"CHI commends the FDA for its recognition of the need for a more efficient regulatory pathway for innovative medical devices that have the potential to improve lives," said CHI President and CEO David L. Gollaher, Ph.D. "It is essential that the FDA maintains focus on initiatives that strengthen the medical device review process, bringing greater clarity and consistency, while ensuring the U.S. maintains its competitive edge."

10 Feb 2011

Pediatricians can play a key role in promoting tobacco-free lifestyle among children, adolescents

Nicotine addiction usually begins during the critical teenage years, and pediatric healthcare professionals can play a prominent role in promoting a tobacco-free lifestyle among children and adolescents, as described in an article published online ahead of print in Pediatric Allergy, Immunology, & Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Cephalon to acquire Alba Therapeutics

Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

10 Feb 2011

Biotechnology News and Research

SynthRx to become wholly-owned subsidiary of ADVENTRX

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Phase III RISE study of Lucentis for DME meets primary endpoint

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

Spinal cord sugar residues regulate growth and survival of nerve cells: Study

Positive data from second study of predictive preterm birth biomarkers presented at SMFM meeting

Dyadic issued seventh U.S. patent

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

Vical 2010 net loss increases to $30.4 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

CHI commends FDA's recognition of more efficient regulatory pathway for innovative medical devices

Pediatricians can play a key role in promoting tobacco-free lifestyle among children, adolescents

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Cephalon to acquire Alba Therapeutics

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News